-       Report 
   - October 2025
    -  197 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - July 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                  -       Report 
   - October 2024
    -  194 Pages 
    
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  194 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - October 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                 -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - July 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - July 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  480 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  482 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  464 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  276 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  383 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  274 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  369 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
             
         The Decongestant market is a subset of the Cough and Cold Drugs market, which includes medications used to treat symptoms of the common cold, such as nasal congestion, sinus pressure, and chest congestion. Decongestants are typically available in both over-the-counter (OTC) and prescription forms, and are often used in combination with other medications to treat cold and flu symptoms. Decongestants work by narrowing the blood vessels in the nasal passages, reducing inflammation and allowing for    easier breathing.
Common OTC decongestants include pseudoephedrine, phenylephrine, and oxymetazoline. Prescription decongestants include ephedrine, phenylephrine, and phenylpropanolamine. Decongestants are also available in combination with other medications, such as antihistamines, expectorants, and cough suppressants.
Some companies in the Decongestant market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less   Read more